Loading ...
Sorry, an error occurred while loading the content.

Fw: NATAP: Intermune HCV protease Starts Study in Europe

Expand Messages
  • Alley Pat
    NATAP http://natap.org/ ... Intermune HCV protease Starts Study in Europe â?oInterMune Presents New Preclinical Data On Its Hepatitis C Virus Protease
    Message 1 of 1 , Jun 1, 2006
    View Source
    • 0 Attachment
      NATAP http://natap.org/
      _______________________________________________



      --------------------------------------------------------------------------------


      Intermune HCV protease Starts Study in Europe

      â?oInterMune Presents New Preclinical Data On Its Hepatitis C Virus Protease Inhibitor At DDWâ?

      Tuesday, May 23, 2006; Posted: 04:13 PM

      Stocks rated 9 and 10 have outperformed the average stock by approximately 14 to 1 since 1995 and ideally are the stocks to focus on each day. Stocks rated 1 and 2 on average have lost money and you want to know these stocks in order to avoid them.

      (RTTNews) - InterMune, Inc. on Tuesday announced the presentation of research describing the preclinical characterization of ITMN-191, its orally available hepatitis C virus NS3/4A protease inhibitor, at the Digestive Disease Week meeting in Los Angeles. The company expects to submit a European Clinical Trial Authorization for ITMN-191 in the third quarter.

      According to the presentation of the preclinical findings, ITMN-191 retains activity against variants that exhibit reduced sensitivity to other experimental hepatitis C virus protease inhibitors in development. A single variant was identified that shows diminished potency to ITMN-191. However, the variant is distinct from variants that have reduced sensitivity to other hepatitis C virus protease inhibitors. This demonstrates a favorable cross-resistance profile of ITMN-191 with other hepatitis C virus protease inhibitors currently in development.

      Also at Digestive Disease Week, the chemical structure of ITMN-191 was revealed for the first time, demonstrating the distinguishing characteristics between ITMN-191 and other experimental HCV protease inhibitors.



      --------------------------------------------------------------------------------


      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.